Financial Data and Key Metrics Changes - The company achieved a 35% year-over-year reduction in pro forma operating expenses, reflecting improved efficiency and focus on portfolio optimization [14][48]. - Cash operating expenses for 2026 are expected to be under $390 million, with a cash balance of $754 million at the end of the previous year, extending the cash runway to early 2028 [48][50]. Business Line Data and Key Metrics Changes - The company reported significant progress in its clinical development, including a positive proof of concept for FAP and multiple milestones achieved with Sanofi, indicating a diversified and advancing clinical portfolio [8][36]. - The AI-enabled chemistry platform has shown to synthesize 90% fewer compounds than industry standards, achieving faster development timelines, with an average of 17 months compared to the industry average of over 42 months [13][43]. Market Data and Key Metrics Changes - The company has generated over $500 million in cumulative cash inflows from partnerships, with potential for over $300 million in milestones per small molecule program, indicating strong market validation and economic potential [35][36]. - The collaboration with Sanofi has advanced five lead packages, contributing to $134 million in milestones to date, showcasing the strength of partnerships in driving market success [36][37]. Company Strategy and Development Direction - The company is focused on three strategic pillars: tangible proof points in clinical and partner programs, surgical investment in its platform, and disciplined execution to maximize impact [10][11]. - The integration of AI across the entire R&D lifecycle is a core strategy, aiming to unlock value through better targets, molecules, and faster program advancements [3][10]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the broader momentum in the biotech sector, emphasizing the importance of translating AI capabilities into real-world applications and measurable impacts [2][3]. - The company is on track for initial engagement with the FDA regarding REC-4881 and anticipates a busy 18-24 months with multiple catalysts expected [51][55]. Other Important Information - The company has built over 50 petabytes of high-quality multimodal data, which is crucial for developing state-of-the-art foundation models in biology and chemistry [40][41]. - The integration of a newly built clinical development AI platform is expected to improve enrollment rates and operational efficiency significantly [44][45]. Q&A Session Summary Question: What potential registrational pathway may look like for REC-4881? - The company is on track for initial engagement with the FDA in the first half of 2026 to discuss the registrational study design and patient population [54][55]. Question: Are there any one-offs that helped in Q4 regarding cost optimization? - The focus has been on efficiency rather than one-off cost cuts, with expectations to continue finding ways to do more with less [56][57]. Question: What is the rationale behind the divestment from NVIDIA? - The divestment is part of NVIDIA's shift in investment strategy, while the technical collaboration with NVIDIA continues to strengthen [60][61].

Financial Data and Key Metrics Changes - The company achieved a 35% year-over-year reduction in pro forma operating expenses, reflecting improved efficiency and focus on portfolio optimization [14][49]. - Cash operating expenses for 2026 are expected to be under $390 million, with a cash balance of $754 million at the end of 2025, extending the cash runway to early 2028 [49][52]. Business Line Data and Key Metrics Changes - The company reported significant progress in its clinical development, including a positive proof of concept for FAP, which has the potential to be a first-in-class treatment [8][18]. - The partnership with Sanofi has resulted in five milestones achieved, contributing to over $500 million in total cash inflows from partnerships [35][36]. Market Data and Key Metrics Changes - The company is leveraging both public and proprietary data to enhance its AI-driven platform, which is critical for generating impactful medicines [5][41]. - The integration of AI across the full life cycle of R&D is seen as a key differentiator in the competitive landscape of the biotechnology industry [2][10]. Company Strategy and Development Direction - The company is focused on three strategic pillars: tangible proof points in clinical and partner programs, surgical investment in its platform, and disciplined execution to maximize impact [10][11]. - The emphasis is on unlocking value through AI-driven insights, improving decision-making across R&D, and ensuring that the platform can deliver better targets and molecules [3][7]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the broader momentum in the biotechnology sector, highlighting the importance of translating AI capabilities into real-world applications [2][4]. - The company is on track for initial engagement with the FDA regarding REC-4881 and anticipates additional clinical data in the coming years [53][57]. Other Important Information - The company has built over 50 petabytes of high-quality multimodal data, which is essential for developing state-of-the-art foundation models in biology and chemistry [40][41]. - The integration of a newly built clinical development AI platform is expected to improve enrollment rates and operational efficiency in clinical trials [46][47]. Q&A Session Summary Question: What is the potential registrational pathway for REC-4881? - The company is on track for initial engagement with the FDA in the first half of 2026 to discuss the registrational study design and patient population [56][57]. Question: Are there any one-off cost-cutting measures that helped in Q4? - The CFO clarified that the focus is on efficiency rather than one-off measures, with expectations to continue finding ways to do more with less [58][60]. Question: What is the rationale behind the divestment from NVIDIA? - The company emphasized that the technical collaboration with NVIDIA continues, while the divestment reflects NVIDIA's shift in investment strategy [62][63].

Financial Data and Key Metrics Changes - The company achieved a 35% year-over-year reduction in pro forma operating expenses, coming in 10% below the guidance provided in May of the previous year [48][49] - The company ended the year with $754 million in cash and expects cash operating expenses for 2026 to be under $390 million, extending the cash runway to early 2028 [48][50] Business Line Data and Key Metrics Changes - The company reported significant progress in its clinical development, with a diversified portfolio and a positive proof of concept for FAP, which has the potential to be a first-in-class treatment [7][27] - The company synthesized 90% fewer compounds than the industry average, achieving 300 compounds synthesized compared to 2,500, and completed this process in an average of 17 months versus the industry standard of over 40 months [13][43] Market Data and Key Metrics Changes - The company has achieved over $500 million in total cash inflows from partnerships, including upfront payments and milestones, with each program having the potential for over $300 million in milestones and tiered royalties [34][35] Company Strategy and Development Direction - The company is focused on three strategic pillars: tangible proof points in clinical and partner programs, surgical investment in its platform, and disciplined execution to do more with less [10][11] - The company aims to leverage its integrated end-to-end operating system to improve decision-making across R&D, emphasizing the importance of high-quality data and innovative models [6][39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the broader momentum in the sector, highlighting the importance of translating insights into real applications and measurable impacts [2][3] - The company is on track for initial engagement with the FDA regarding REC-4881 and anticipates additional clinical data for various programs in the coming year [51][52] Other Important Information - The company has built over 50 petabytes of high-quality multimodal data, which is crucial for developing state-of-the-art foundation models in biology and chemistry [39][40] - The company continues to innovate in its clinical development AI platform, improving enrollment rates and operational efficiency [45][46] Q&A Session Summary Question: What is the potential registrational pathway for REC-4881? - The company is on track for initial engagement with the FDA in the first half of 2026 to discuss the registrational study design and patient population [54][55] Question: Are there any one-off cost-cutting measures that helped in Q4? - The focus has been on efficiency rather than one-off cost-cutting measures, with expectations to continue growing the pipeline while hitting cost targets [56][57] Question: What is the rationale behind the divestment from NVIDIA? - The divestment is part of NVIDIA's shift in investment strategy, while the technical collaboration with NVIDIA continues, focusing on leveraging automation and supercomputing capabilities [59][60]